| 000 | 01836 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515122749.0 | ||
| 264 | 0 | _c20080807 | |
| 008 | 200808s 0 0 eng d | ||
| 022 | _a1556-1380 | ||
| 024 | 7 |
_a10.1097/JTO.0b013e3181729299 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFlorescu, Marie | |
| 245 | 0 | 0 |
_aA clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. _h[electronic resource] |
| 260 |
_bJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer _cJun 2008 |
||
| 300 |
_a590-8 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
| 650 | 0 | 4 | _aErlotinib Hydrochloride |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aOntario _xepidemiology |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aQuinazolines _xadministration & dosage |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aHasan, Baktiar | |
| 700 | 1 | _aSeymour, Lesley | |
| 700 | 1 | _aDing, Keyue | |
| 700 | 1 | _aShepherd, Frances A | |
| 773 | 0 |
_tJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer _gvol. 3 _gno. 6 _gp. 590-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/JTO.0b013e3181729299 _zAvailable from publisher's website |
| 999 |
_c18013555 _d18013555 |
||